Logo
x

Search

Subscribe Now

Chronic Inflammatory Disorders

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

  • April 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.